ArticleJournal of proteome research2026
ProteoForge: An Imputation-Aware Framework for Differential Proteoform Discovery in Bottom-Up Proteomics.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human genome contains approximately 20,000 protein-coding genes. However, millions of diverse protein variants, called proteoforms, exist. Despite originating from the same gene, proteoforms often have distinct biological roles. In bottom-up proteomics, the aggregation of peptide measurements into protein-level quantities often obscures this information. Existing methods for differential proteoform discovery are limited by their handling of missing data, which can introduce a significant bias. To address this, we developed ProteoForge, which builds on an imputation-aware statistical model to identify and group covarying peptides into quantitatively differential proteoforms (dPFs). Benchmarking against existing methods demonstrated that ProteoForge provides high accuracy and stability in data sets with high rates of missing values, complex experimental designs, or varying signal strengths. Application of ProteoForge to proteomics data from lung cancer cells under hypoxia revealed extensive proteoform-level regulation hidden by a standard protein-level analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.